Nisa Investment Advisors LLC Sells 1,912 Shares of IDEXX Laboratories, Inc. $IDXX

Nisa Investment Advisors LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 38,254 shares of the company’s stock after selling 1,912 shares during the quarter. Nisa Investment Advisors LLC’s holdings in IDEXX Laboratories were worth $24,440,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of IDEXX Laboratories by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after purchasing an additional 54,402 shares during the period. Bank of New York Mellon Corp increased its stake in IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after buying an additional 884,808 shares in the last quarter. William Blair Investment Management LLC raised its holdings in IDEXX Laboratories by 7.5% during the second quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock valued at $367,440,000 after acquiring an additional 47,977 shares during the period. Legal & General Group Plc lifted its position in shares of IDEXX Laboratories by 1.8% in the second quarter. Legal & General Group Plc now owns 648,626 shares of the company’s stock valued at $347,884,000 after acquiring an additional 11,768 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of IDEXX Laboratories by 6.9% in the second quarter. Franklin Resources Inc. now owns 592,649 shares of the company’s stock worth $317,862,000 after acquiring an additional 38,202 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Barclays assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 target price for the company. Finally, Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Trading Up 0.1%

IDXX stock opened at $713.35 on Friday. The firm has a market cap of $56.96 billion, a PE ratio of 56.57, a price-to-earnings-growth ratio of 3.81 and a beta of 1.67. The firm has a fifty day moving average price of $706.93 and a 200 day moving average price of $643.06. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $2.80 earnings per share. IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.